Table 3.
Summary of drugs being repurposed in clinical trials against COVID-19.
| Therapeutic Intervention | Class of the Drug/s | Clinical Condition/s of the Participants of the Trial | Trial Identification Number * | Phase |
|---|---|---|---|---|
| Hydroxychloroquine | Antimalarial and amebicide | 30 patients suffering from pneumonia due to COVID-19 | NCT04261517 | 3 |
| Chloroquine | Antimalarial and amebicide | 10,000 patients in a prophylaxis study for COVID-19 | NCT04303507 | N/A |
| Human immunoglobulin | Antibody | 80 patients suffering from pneumonia due to COVID-19 | NCT04261426 | 2 and 3 |
| Remdesivir | Nucleotide reverse transcriptase inhibitor | 452 patients suffering from a severe respiratory infection due to COVID-19 | NCT04257656 | 3 |
| Remdesivir | Nucleotide reverse transcriptase inhibitor | 308 patients with mild or moderate respiratory tract infection caused by COVID-19 | NCT04252664 | 3 |
| Arbidol (umifenovir) | Virus entry (Fusion) inhibitor | 380 patients suffering from Pneumonia caused by COVID-19 | NCT04260594 | 4 |
| Arbidol or lopinavir-ritonavir or oseltamivir | Combination of virus entry (Fusion) inhibitor and protease inhibitor | 400 patients infected with COVID-19 | NCT04255017 | 4 |
| Arbidol or lopinavir + ritonavir | Combination of virus entry (Fusion) inhibitor and protease inhibitor | 125 patients infected with COVID-19 | NCT04252885 | 4 |
| Darunavir + cobicistat | Protease inhibitor (Darunavir) in combination with Booster (cobicistat, a CYP3A inhibitor) | 30 patients suffering from Pneumonia caused by COVID-19 | NCT04252274 | 3 |
| TCM combination with lopinavir + ritonavir, α-interferon via aerosol | Cytokine in combination with protease inhibitor | 150 patients infected with COVID-19 | NCT04251871 | N/A |
| Recombinant human interferon α2β | Cytokine | 328 patients infected with COVID-19 | NCT04293887 | 1 |
| Carrimycin or lopinavir + ritonavir or arbidol or chloroquine phosphate | Antibiotic in combination with booster (arbidol) or antimalarial/ amebicide | 520 patients infected with COVID-19 | NCT04286503 | 4 |
| Danoprevir + ritonavir + interferon inhalation or lopinavir + ritonavir or TCM plus interferon inhalation | Protease inhibitors with cytokine as aerosol | 50 patients suffering from pneumonia caused by COVID-19 | NCT04291729 | 4 |
| Xiyanping or lopinavir-ritonavir-interferon inhalation | Anti-inflammatory (Xiyanping) or Protease inhibitors with cytokine | 384 patients with pneumonia caused by COVID-19 | NCT04275388 | N/A |
| Xiyanping combined with lopinavir + ritonavir | Anti-inflammatory (Xiyanping) in combination with Protease inhibitors | 80 patients infected with COVID-19 | NCT04295551 | N/A |
| Combinations of oseltamivir, favipiravir, and chloroquine | Neuraminidase (Oseltamivir) in combination with antimalarial/ amebicide | 80 patients infected with COVID-19 | NCT04303299 | 3 |
| Thalidomide | Angiogenesis inhibitor and immunomodulator | 40 patients infected with COVID-19 | NCT04273581 | 2 |
| Thalidomide | Angiogenesis inhibitor and immunomodulator | 100 patients suffering from pneumonia caused by COVID-19 | NCT04273529 | 2 |
| Vitamin C | Vitamin (Ascorbic acis) | 140 patients with severe pneumonia caused by COVID-19 | NCT04264533 | 2 |
| Methylprednisolone | Corticosteroid | 80 patients infected with COVID-19 | NCT04244591 | 2 |
| Pirfenidone | Pyridone | 294 patients with severe pneumonia caused by COVID-19 | NCT04282902 | 3 |
| Bromhexine hydrochloride | Mucolytics | 60 patients with suspected and mild pneumonia caused by COVID-19 | NCT04273763 | N/A |
| Bevacizumab | Monoclonal antibody | 20 patients with COVID-19 associated with severe pneumonia | NCT04275414 | 2 and 3 |
| Fingolimod | Sphingosine 1-phosphate receptor modulator | 30 patients infected with COVID-19 | NCT04280588 | N/A |
* Information source: clinicaltrial.gov. N/A = Not available.